TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
- PMID:16357130
- DOI: 10.1158/0008-5472.CAN-05-2801
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its agonistic antibodies, which are currently in early clinical trials for treating various malignancies, induce apoptosis through triggering of either TRAIL-R1 or TRAIL-R2. Based on studies using agonistic monoclonal antibodies, we recently proposed that primary chronic lymphocytic leukemic cells seem to signal apoptosis primarily through TRAIL-R1. We have now synthesized mutant forms of TRAIL specific for TRAIL-R1 or TRAIL-R2. The selectivity of these mutants to induce apoptosis in cell lines is due to selective binding to their cognate receptors resulting in apoptosis via formation of a death-inducing signaling complex. Using these mutants, we now unequivocally show that primary cells from patients with chronic lymphocytic leukemia and mantle cell lymphoma signal to apoptosis almost exclusively through TRAIL-R1. Thus, no significant therapeutic benefit can be anticipated from treating such patients with agents currently in clinical trials that signal predominantly through TRAIL-R2, such as HGS-ETR2 or Apo2L/TRAIL. Our study highlights the necessity to determine whether primary cells from a particular tumor signal via TRAIL-R1 or TRAIL-R2. Such information will provide a rational approach to optimize TRAIL therapy.
Similar articles
- Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM.MacFarlane M, et al.Cell Death Differ. 2005 Jul;12(7):773-82. doi: 10.1038/sj.cdd.4401649.Cell Death Differ. 2005.PMID:15861184
- Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM.MacFarlane M, et al.Oncogene. 2002 Oct 3;21(44):6809-18. doi: 10.1038/sj.onc.1205853.Oncogene. 2002.PMID:12360407
- Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A.Georgakis GV, et al.Br J Haematol. 2005 Aug;130(4):501-10. doi: 10.1111/j.1365-2141.2005.05656.x.Br J Haematol. 2005.PMID:16098063
- TRAIL and chemotherapeutic drugs in cancer therapy.Wu XX, Ogawa O, Kakehi Y.Wu XX, et al.Vitam Horm. 2004;67:365-83. doi: 10.1016/S0083-6729(04)67019-1.Vitam Horm. 2004.PMID:15110186Review.
- Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.Cha SS, Song YL, Oh BH.Cha SS, et al.Vitam Horm. 2004;67:1-17. doi: 10.1016/S0083-6729(04)67001-4.Vitam Horm. 2004.PMID:15110168Review.
Cited by
- Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis.Vindrieux D, Réveiller M, Chantepie J, Yakoub S, Deschildre C, Ruffion A, Devonec M, Benahmed M, Grataroli R.Vindrieux D, et al.Cancer Cell Int. 2011 Dec 2;11:42. doi: 10.1186/1475-2867-11-42.Cancer Cell Int. 2011.PMID:22136382Free PMC article.
- The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G.Athanasakis E, et al.Oncotarget. 2014 Dec 30;5(24):12635-45. doi: 10.18632/oncotarget.2211.Oncotarget. 2014.PMID:25587027Free PMC article.
- Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway.Wang L, Deng R, Chen S, Tian R, Guo M, Chen Z, Zhang Y, Li H, Liu Q, Tang S, Zhu H.Wang L, et al.Cell Death Dis. 2023 Dec 4;14(12):793. doi: 10.1038/s41419-023-06327-5.Cell Death Dis. 2023.PMID:38049405Free PMC article.
- Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.Zhang P, Zheng Y, Shi J, Zhang Y, Liu S, Liu Y, Zheng D.Zhang P, et al.J Biol Chem. 2010 Mar 19;285(12):8953-66. doi: 10.1074/jbc.M109.070680. Epub 2010 Jan 27.J Biol Chem. 2010.PMID:20106985Free PMC article.
- GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation.Moriwaki K, Shinzaki S, Miyoshi E.Moriwaki K, et al.J Biol Chem. 2011 Dec 16;286(50):43123-33. doi: 10.1074/jbc.M111.262741. Epub 2011 Oct 25.J Biol Chem. 2011.PMID:22027835Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous